Developing biologics, delivering patient care.
Biopartners is dedicated to improving quality of life through significant advancements in patient care. We are a dynamic and growing biopharmaceutical company, leading the development of biopharmaceutical products in the fields of endocrinology, multiple sclerosis and virology. Our comprehensive product portfolio consists of first-generation biopharmaceuticals with innovative-formulations or novel delivery systems.

A Pioneer in Biopharmaceuticals

We are the first company to receive a marketing authorisation in the EU, Norway and Iceland for a prolonged-release formulation of recombinant human growth hormone (rhGH) which will cut the number of self-administered injections from once-a-day to once-a-week - a major breakthrough in rhGH treatment.